Cadila Healthcare Limited Adalimumab Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Adalimumab Export Records India — #3 Exporter, 4 Shipments, $37.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Adalimumab

India Pharmaceutical Trade Intelligence

$1.2M67 Suppliers53 CountriesHS 30021500

ExportsIndia → VENEZUELA27.9%India → SRI LANKA20.0%

ImportsUNITED STATES → India$167.7K UNITED KINGDOM → India$28.5K

#1 Supplier: RELIANCE LIFE

Cadila Healthcare Limited — Adalimumab Exporter #3 | $37.5K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Adalimumab Exporter Profile

Indian Pharmaceutical Exporter · #3 for Adalimumab · $37.5K export value · DGFT Verified

Cadila Healthcare Limited is the #3 Indian exporter of Adalimumab with $37.5K in export value and 4 verified shipments. Cadila Healthcare Limited holds a 3.1% market share in Adalimumab exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Adalimumab Export Profile: Buyers & Destinations

Cadila Healthcare Limited Adalimumab export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Adalimumab?

Country	Value	Shipments	Share
SRI LANKA	$200.0K	4	28.8%
NEPAL	$130.3K	29	18.8%
UNITED ARAB EMIRATES	$78.9K	7	11.4%
VENEZUELA	$50.0K	1

Who Are the Top Buyers of Adalimumab from India?

Buyer	Country	Value	Orders
D. K. M. PHARMACEUTICALS PVT. LTD.	NEPAL	$49.8K	17
D K M PHARMACEUTICALS PRIVATE LIMITED	NEPAL	$35.1K	3
UNITED STATES PHARMACOPEIAL CONVEN	UNITED STATES	$25.4K	5
PHARMACHEM PRIVATE LIMITED	NEPAL	$22.7K	4
D K M PHARMACEUTICALS PVT LTD	NEPAL	$20.5K	4
RADEEP SERVICES	SINGAPORE	$13.6K	12
IMAD SOUHEL ANDRAOS	UNITED ARAB EMIRATES	$13.5K	2
BY THE ORDERING OF	TURKS AND CAICOS	$8.5K	6
TO THE CONSIGNEE-	KENYA	$7.8K	4

India's Adalimumab is purchased by 97 buyers worldwide. The top buyer is D. K. M. PHARMACEUTICALS PVT. LTD. (NEPAL), followed by D K M PHARMACEUTICALS PRIVATE LIMITED and UNITED STATES PHARMACOPEIAL CONVEN.

How Does Cadila Healthcare Limited Compare to Nearest Adalimumab Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	RELIANCE LIFE SCIENCES PRIVATE LIMITED	$338.1K	20	10	$16.9K
2	ZYDUS LIFESCIENCES LIMITED	$66.8K	22	3	$3.0K
3	CADILA HEALTHCARE LIMITED ★	$37.5K	4	1	$9.4K
4	PHARMA CHOICE LLP	$26.7K	23	4	$1.2K
5	REMEDI PHARMA DISTRIBUTORS	$25.4K	5	1	$5.1K

Cadila Healthcare Limited ranks #3 among 67 Indian Adalimumab exporters. Average shipment value of $9.4K compared to the market average of $8.2K. The closest competitors by value are RELIANCE LIFE SCIENCES PRIVATE LIMITED and ZYDUS LIFESCIENCES LIMITED.

Which Indian Ports Ship Adalimumab Exports?

Port	Shipments	% Share
SAHAR AIR	55	24.7%
SAHAR AIR CARGO ACC (INBOM4)	47	21.1%
DELHI AIR CARGO ACC (INDEL4)	23	10.3%
Bombay Air	17	7.6%
DELHI AIR	11	4.9%
Madras Air	6	2.7%
HYDERABAD ACC (INHYD4)	5	2.2%
AHEMDABAD AIR	5	2.2%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Adalimumab Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Adalimumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 53+ countries, 97+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Adalimumab

Adalimumab

Cadila Healthcare Limited — Adalimumab Exporter Profile

Cadila Healthcare Limited — Adalimumab Export Profile: Buyers & Destinations

Where Does India Export Adalimumab?

Who Are the Top Buyers of Adalimumab from India?

What Is India's Total Adalimumab Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Adalimumab Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Adalimumab Exporters?

How Does Cadila Healthcare Limited Compare to Nearest Adalimumab Exporters?

Which Indian Ports Ship Adalimumab Exports?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Adalimumab Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Adalimumab Export Data from Cadila Healthcare Limited

Adalimumab Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source